Akums Drugs and Pharmaceuticals Limited (AKUMS) — Announcement | 8 August 2026

8 August 2026 · NSE Neutral

By StockFin Research Team•AI-Assisted Analysis•Source: BSE/NSE Filings

📢 Key Event

Q1 FY27 results show 13.9% revenue growth and 35.4% EBITDA increase.

🔄 What Changed

Revenue grew 13.9% YoY; EBITDA up 35.4% YoY; capacity utilization improved to 50%; API pricing increased; PAT up 56.1% YoY.

🔮 What's Next

Improved performance expected from domestic branded formulations segment; international business to return to growth; acquisition to boost margins and tap niche formulations.

💡 Investor Takeaway

Shareholders see stronger profitability from CDMO and API segments, with strategic expansion into skincare through the Oriflame acquisition.

Akums Drugs and Pharmaceuticals reported Q1 FY27 revenue of ₹1,167 crores (+13.9% YoY) driven by CDMO growth, while EBITDA rose 35.4% YoY to ₹175 crores. The company acquired Oriflame India's manufacturing business for Rs 56 Crore to expand into skincare and wellness, and highlighted improved API pricing and capacity utilization at 50%. PAT grew 56.1% YoY to ₹101 crores, reflecting stronger margins in CDMO and API segments.

📄 View Original Announcement (PDF)

📊 Stock Analysis — AKUMS ✨ Ask AI About This

About Akums Drugs and Pharmaceuticals Limited (AKUMS)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹12,594.67 CrP/E: 42.0ROE: 8.8%ROCE: 15.4%Div Yield: 0.37%

View full AKUMS stock details →

📡 Get AI alerts when AKUMS files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track AKUMS — Free

💡 Ask AI about this filing

"How will the Oriflame acquisition impact margins?""What is the revenue contribution from the new skincare segment?""When will API pricing volatility stabilize?"

Ask AI Free →

📊 More AKUMS filings

Announcement — 25 September 2026Akums Drugs & Pharmaceuticals announced that its insider trading compliance window closes on October...
🔴 Announcement — 23 September 2026Akums Drugs & Pharmaceuticals announced its schedule for two institutional investor meetings on Sept...
🔴 Announcement — 16 September 2026Akums Drugs & Pharmaceuticals announced its participation in a scheduled investor and analyst meet o...
🔴 Announcement — 3 September 2026Akums Drugs & Pharmaceuticals announced it received an ESG rating of 65 from NSE Sustainability for ...
Announcement — 25 August 2026Akums Drugs and Pharmaceuticals announced its participation in scheduled investor and analyst meetin...

See all AKUMS filings →

🔥 Also filed on 8 August 2026

SURYALAXMISuryalakshmi Cotton Mills LimitedFinancial Results LAMBODHARALambodhara Textiles LimitedFinancial Results ABFRLAditya Birla Fashion and Retail LimitedFinancial Results LAMBODHARALambodhara Textiles LimitedCorporate Action ADANIENTAdani Enterprises LimitedAnnouncement ABFRLAditya Birla Fashion and Retail LimitedFinancial Results

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when AKUMS files new disclosures

Track AKUMS filings, board meetings, and corporate actions. Free email alerts at 5 PM.